Cooley Partner Quoted About H1 2024 Healthcare Deals

Cooley partner Kate Hillier was quoted in two Law360 articles about healthcare dealmaking trends and the most influential healthcare deals in the first half of 2024. Hillier highlighted the uptick in antibody-drug conjugate (ADC) deals in reference to Genmab’s and Merck’s respective deals in the ADC space in April 2024, as well as pharmaceutical deals. Cooley also was noted for advising SystImmune on its exclusive license and collaboration agreement with Bristol Myers Squibb, which closed in April 2024.

Read “Healthcare Dealmaking Trends of 2024: A Midyear Review" (subscription required)

Read “The Most Influential Healthcare Deals So Far in 2024" (subscription required)

This content is provided for general informational purposes only, and your access or use of the content does not create an attorney-client relationship between you or your organization and Cooley LLP, Cooley (UK) LLP, or any other affiliated practice or entity (collectively referred to as “Cooley”). By accessing this content, you agree that the information provided does not constitute legal or other professional advice. This content is not a substitute for obtaining legal advice from a qualified attorney licensed in your jurisdiction and you should not act or refrain from acting based on this content. This content may be changed without notice. It is not guaranteed to be complete, correct or up to date, and it may not reflect the most current legal developments. Prior results do not guarantee a similar outcome. Do not send any confidential information to Cooley, as we do not have any duty to keep any information you provide to us confidential. This content may be considered Attorney Advertising and is subject to our legal notices.